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https://doi.org/10.1016/j.molcel.2021.01.011SUMMARYDNA methylation is implicated in neuronal biology via the protein MeCP2, the mutation of which causes Rett
syndrome. MeCP2 recruits the NCOR1/2 co-repressor complexes to methylated cytosine in the CG dinucle-
otide, but also to sites of non-CG methylation, which are abundant in neurons. To test the biological signif-
icance of the dual-binding specificity of MeCP2, we replaced its DNA binding domain with an orthologous
domain from MBD2, which can only bind mCG motifs. Knockin mice expressing the domain-swap protein
displayed severe Rett-syndrome-like phenotypes, indicating that normal brain function requires the interac-
tion of MeCP2 with sites of non-CG methylation, specifically mCAC. The results support the notion that the
delayed onset of Rett syndrome is due to the simultaneous post-natal accumulation of mCAC and its reader
MeCP2. Intriguingly, genes dysregulated in both Mecp2 null and domain-swap mice are implicated in other
neurological disorders, potentially highlighting targets of relevance to the Rett syndrome phenotype.INTRODUCTION
Heterozygous loss-of-function mutations in the X-linkedMECP2
gene result in Rett syndrome (RTT), a neurological disorder
affecting 1 in 10,000 live female births (Amir et al., 1999).
MeCP2 protein was initially identified by its ability to bind meth-
ylated CG dinucleotides and shown to repress transcription via
the recruitment of histone deacetylase complexes (Lewis et al.,
1992; Nan et al., 1997, 1998). Recent evidence indicates that
MeCP2 negatively regulates the expression of hundreds of
genes via the recruitment of the HDAC3-containing NCOR1/2
co-repressor complexes (Cholewa-Waclaw et al., 2019; Gabel
et al., 2015; Lagger et al., 2017; Lyst et al., 2013). In the absence
of functional MeCP2, indirect mechanisms also lead to the
downregulation of many genes, perhaps connected with a global
reduction in total RNA levels (Kinde et al., 2016; Lagger et al.,
2017; Li et al., 2013; Yazdani et al., 2012). Thismultitude of subtle
changes to neuronal gene expression is thought to underlie RTT.
In addition to canonical mCG dinucleotides in duplex DNA,
MeCP2 targets 5-methylcytosine in a non-CG context (or
mCH, where H = A, C, or T). This study focuses on the biological
significance of this dual DNA-binding specificity. During early1260 Molecular Cell 81, 1260–1275, March 18, 2021 ª 2021 The Auth
This is an open access article under the CC BY license (http://creativemammalian embryogenesis, the methylation of CG dinucleo-
tides is at first depleted, then re-established, reaching high levels
in the bulk genome while absent at unmethylated CpG islands
(Bird et al., 1985; Deaton and Bird, 2011). De novo CG methyl-
ation is laid down by the DNA methyltransferases DNMT3A
and DNMT3B and is maintained through cell division by the ac-
tion of DNMT1 at hemi-methylated sites (Reik, 2007). Unlike
plants, which have specific DNA methyltransferases that target
CHG and CHH sites (Wendte and Schmitz, 2018), mCH in mam-
mals relies on ‘‘off-target’’ activity by DNMT3A and DNMT3B
(Gabel et al., 2015; Guo et al., 2014; Lister et al., 2013; Ramsa-
hoye et al., 2000; Stroud et al., 2017). There appears to be no
mechanism to maintain asymmetrical CH methylation, which
means that CH methylation is lost in replicating cells (He and
Ecker, 2015). Post-mitotic neurons are unique among mamma-
lian somatic cell types in that they accumulate high levels of
CH methylation, most prevalently in CAC trinucleotides (Guo
et al., 2014; Varley et al., 2013; Xie et al., 2012). This modification
arises postnatally due to high levels of DNMT3A, which persist
throughout adulthood (Feng et al., 2005; Stroud et al., 2017).
The discovery that MeCP2 targets mCAC sites preferentially
over all other forms of mCH (Gabel et al., 2015; Lagger et al.,ors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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that this DNA-binding specificity contributes to neuronal func-
tion. Non-CG methylation almost doubles the number of avail-
able MeCP2 binding sites in neurons (Lagger et al., 2017; Lister
et al., 2013; Mo et al., 2015), and the timing of increased CAC
methylation coincides with the increase in neuronal MeCP2 pro-
tein levels during the first few weeks of life (Guo et al., 2014;
Lister et al., 2013; Skene et al., 2010; Stroud et al., 2017).
It is difficult to disentangle the influence of mCG versus
mCAC on the regulation of gene expression by MeCP2, as
these marks are interspersed with one another (Guo et al.,
2014; Lavery et al., 2020). In the present study, we have as-
sessed their relative importance using molecular genetic ap-
proaches to separate the effects of mCG and mCAC on
MeCP2 function. We directly visualized footprints of MeCP2
bound to mCG and mCAC in native brain chromatin, as well
as a subtle footprint over the rarer motif, mCAT (Lagger et al.,
2017). To determine the biological importance of the ability of
MeCP2 to bind mCAC sites, we took advantage of the fact
that the conserved methyl-CpG binding domain (MBD) of the
related protein, MBD2, confers binding to mCG sites only.
This allowed us to create a chimeric MeCP2-MBD2 (MM2)
protein by domain swapping. Despite the retention of mCG
binding, knockin mice expressing MM2 developed severe
phenotypic features that largely mirrored those seen in mouse
models of RTT. We conclude that binding to mCG alone is
insufficient for MeCP2 to fulfill its role in the maintenance of
neurological function. At a molecular level, the inability to bind
mCAC leads to global transcriptional changes in MM2 mice,
with one-third of dysregulated genes also altered in Mecp2
null mice. Intriguingly, this shared subset is mostly upregulated,
highly methylated, and enriched for genes associated with
neurological disease, highlighting potentially important contrib-
utors to the RTT-like phenotype.
RESULTS
MeCP2 footprints in native brain chromatin
MeCP2 binding tomCG andmCAC sites has been characterized
in vitro using multiple techniques, and the co-crystal structures
of both of these interactions have been solved (Ho et al., 2008;
Lagger et al., 2017; Lei et al., 2019; Lewis et al., 1992; Mellén
et al., 2012; Sperlazza et al., 2017). A third potential MeCP2 bind-
ing motif, mCAT, has been proposed, although this interaction
appears to be weaker and is barely detectable in some assays
(Lagger et al., 2017; Liu et al., 2018).We used BLI (bio-layer inter-
ferometry) to quantify the interactions between the MBD of
MeCP2 and DNA probes containing each of three methylatedFigure 1. MeCP2 binds mCG and mCAC, and to a lesser extent, mCAT
(A) Bio-layer interferometry (BLI) analysis of the interaction between the MBD of M
site. KD values: mCG 22.25 ± 3.12 nM; mCAC 13.90 ± 0.64 nM; mCAT 63.71 ±
significant [NS] p = 0.06); binding to mCAT is significantly weaker than mCG and
(B) Western blot analysis of MeCP2 following pull-down from rat brain nuclear e
CAC, and CAT (top) and unbound MeCP2 in the supernatant (bottom).
(C) Whole-genome bisulfite sequencing analysis in the mouse hypothalamus (Lagg
(top) and each CAN trinucleotide (bottom). Sites were binned by level of methyla
(D–F) ATAC-seq footprinting analysis of MeCP2 over methylated (top) and unmeth
1262 Molecular Cell 81, 1260–1275, March 18, 2021motifs (Figure 1A). MeCP2 binds to both mCG and mCAC, with
dissociation constants (KD) of 22.25 ± 3.12 and 13.90 ±
0.64 nM, respectively. In contrast, binding to mCAT is 3- to
5-fold weaker, with a KD of 63.17 ± 6.94 nM. Previously, full-
length MeCP2 was shown to bind readily to all three sequences
when co-overexpressed with methylated oligonucleotides in
HEK293 cells (Lagger et al., 2017). To assess this further, we
used beads coated with double-stranded oligonucleotides to
pull down endogenous MeCP2 from rat brain lysates. Like
mCG and mCAC (Connelly et al., 2020), mCAT-containing DNA
efficiently enriched MeCP2 protein in a DNAmethylation-depen-
dent manner (Figure 1B). Defining MeCP2 binding sites in native
brain chromatin has proven more challenging due to the high
abundance of both MeCP2 protein and its short target se-
quences. Also, the proportion of methylation at individual mCH
motifs is, on average, low, in contrast to CGs that are each highly
methylated in the bulk genome (Figure 1C). Chromatin immuno-
precipitation sequencing (ChIP-seq) analysis gives a relatively
featureless signal across the genome, except for a sharp drop
at non-methylated CpG islands (Chen et al., 2015; Kinde et al.,
2016; Lagger et al., 2017; Skene et al., 2010). Nevertheless,
peak-calling algorithms detect enrichment in vivo of mCG and
mCAC (but not mCAT), coincident with the summits of MeCP2
binding (Cholewa-Waclaw et al., 2019; Gabel et al., 2015; Lagger
et al., 2017). To test the specificity of genomic binding more
robustly, we adopted the assay for transposase-accessible
chromatin using sequencing (ATAC-seq) to reveal MeCP2-spe-
cific footprints (Figure S1A). By dividing the ATAC-seq signal
from wild-type (WT) samples by the equivalent signal from
Mecp2 null (knockout [KO]) samples, the method has revealed
protected genomic regions attributable to MeCP2 at mCG in
cultured human neurons (Cholewa-Waclaw et al., 2019). Here,
we detect a MeCP2 binding footprint over methylated CG dinu-
cleotides in mouse hypothalamus (Figure 1D). To visualize a
MeCP2 binding footprint at mCAC sites with this method, we
focused on the subset of sites with >75% methylation (Figures
1E and S1B). The greater prominence of the mCAC footprint
compared to the mCG footprint in the hypothalamus does not
signify stronger binding to the trinucleotide motif, due to several
unquantifiable factors, including site selection criteria and
sequence context (e.g., methylated tandem CAC repeats). Foot-
prints were not initially detectable atmCAT, but by lowering strin-
gency to exclude sites <50% methylated (Figure S1B), a subtle
footprint at mCAT was observed, but not at other mC-containing
motifs (Figures 1F and S1C–S1F). No footprints were detected at
unmethylated cytosine in any sequence context (Figures 1D–1F
and S1C–S1F). We conclude that the main binding sites for
MeCP2 are mCG and mCAC. While binding to mCAT moietieseCP2 and methylated DNA probes containing a single mCG, mCAC, or mCAT
6.94 nM (means ± SEMs). Binding affinity to mCG and mCAC is similar (not
mCAC (**p = 0.006 and **p = 0.002, respectively), t tests.
xtracts using immobilized DNA containing unmethylated and methylated CG,
er et al., 2017) showing the distribution of methylation at each CN dinucleotide
tion.
ylated (bottom) CG (D), CAC (E), and CAT (F) sites in the mouse hypothalamus.
A
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its reduced affinity and lower abundance.
A chimeric MeCP2 that selectively binds mCG
To determine the biological importance of the dual-binding
specificity of MeCP2, we sought to modify MeCP2 so that it
bound to only one of these motifs. A DNA binding domain that
exclusively binds mCAC is unavailable, but domains that only
bindmCG are present in other members of theMBD protein fam-
ily. In particular, the evolutionarily most ancient member of the
MBD family, MBD2 (Hendrich and Bird, 1998; Tweedie et al.,
1999), is reported to only bind to mCG (Guo et al., 2014; Liu
et al., 2018). We substituted the MeCP2 MBD (residues 94–
164) with the equivalent domain from MBD2 (residues 153–
217) to create a chimeric ‘‘MM2’’ protein (Figures 2A and 2B). Af-
ter confirming by electrophoretic mobility shift assay (EMSA)
analysis that the MBD of MBD2 readily binds to mCG only (Fig-
ure 2C), we performed a similar analysis using N-terminal frag-
ments of MM2 and WT MeCP2. As anticipated, MM2 adopted
the binding specificity of MBD2, displaying affinity for a DNA
probe containing mCG but no affinity for the mCAC probe
(Figure 2D).
To test the ability of the chimeric protein to bind mCG sites
in vivo, we transiently overexpressed the EGFP-tagged MM2 in
culturedmouse fibroblasts, in whichmCG is highly concentrated
in heterochromatic foci (Nan et al., 1996). MM2-EGFP colocal-
ized efficiently with pericentromeric heterochromatin in amanner
indistinguishable from WT-EGFP (Figure 2E). To confirm that
mCG binding is mediated by the introduced MBD, we showed
that mutation of the essential arginine equivalent to R111 of
MeCP2 (see Figure 2A) to glycine (Kudo et al., 2003) disrupts
the localization of MeCP2 (Figure 2E). To assess the binding dy-
namics between MM2-EGFP and heterochromatin, we per-
formed transient transfection followed by fluorescence recovery
after photobleaching (FRAP). WT-EGFP binding recovered with
a half-life of 34.7 ± 2.3 s (Figure 2F), consistent with previous
studies (Ghosh et al., 2010; Klose et al., 2005; Ludwig et al.,
2017). The half-life of MM2-EGFP was 20.5 ± 2.9 s, indicating
that the chimeric protein exchanges slightly faster (p < 0.0001,
Mann-Whitney test). This may reflect a somewhat reduced bind-
ing affinity for mCG, as also suggested by the lower fraction ofFigure 2. Chimeric protein MM2 has the DNA binding properties of MB
(A) Alignment of human (h) andmouse (m)MeCP2, MBD2,MBD1, andMBD4, shad
missense mutations within the MBD (red, above); conserved arginine at position
MM2 (shaded in orange).
(B) Schematic showing the design of the chimeric protein MM2, where the MBD o
replace the endogenous MBD (residues 94–164). MM2 was tagged at the C term
(C) EMSA analysis of the MBD of human MBD2 (2 mM) binding to DNA probes c
fication is shown below (means ± SEMs).
(D) EMSA analysis of N-terminal fragments (residues 1–205) of wild-type (WT) MeC
concentrations 0–4.5 mM). Quantification is shown below (means ± SEMs). Bindin
0.613; mCG WT versus MM2, ****p < 0.0001.
(E) Representative images showing localization of EGFP-tagged MeCP2 (WT) a
expression in mouse fibroblasts. Mutation of the MBD (R111G and the equivale
bar, 10 mm.
(F) FRAP analysis at heterochromatic foci. Total numbers of cells analyzed: WT-E
fluorescence relative to prebleach, means ± SEMs. Half-lives: WT-EGFP = 34.
compared using a Mann-Whitney test: ****p < 0.0001.
1264 Molecular Cell 81, 1260–1275, March 18, 2021probe bound in the EMSA assay (Figure 2D). Notably, this differ-
ence is much less severe than that of RTT-causing mutations
within the MBD domain (Ballestar et al., 2000; Schmiedeberg
et al., 2009).
The key function of MeCP2 is to form a bridge between meth-
ylated DNA and the NCOR1/2 co-repressor complexes depen-
dent on the MBD and NID (NCOR1/2 interaction domain),
respectively (Guy et al., 2018; Kruusvee et al., 2017; Lyst et al.,
2013; Tillotson et al., 2017). MM2 retains the NID (residues
298–309) and, as expected, was able to pull down NCOR1/2
complex subunits HDAC3 and NCOR1 when transiently overex-
pressed in HeLa cells (Figure S2A). Likewise, MM2 retains the
ability to recruit TBL1X (its direct binding partner in the
NCOR1/2 complexes) to mCG-rich heterochromatic foci when
co-expressed in cultured fibroblasts (Figure S2B). The NID-abol-
ishing RTT mutation R306C served as a negative control in both
of these assays (Lyst et al., 2013). Overall, the behavior ofMM2 in
all in vitro and cell culture-based assays supports the notion that
this chimeric protein retains the essential properties of MeCP2,
with the major exception that its DNA binding is restricted to
mCG sites.
MM2 selectively binds mCG in vivo in knockin mice
To determine the function of MM2 in vivo, we produced knockin
mice by replacing the endogenous Mecp2 allele with DNA
sequence encoding MM2 fused to a C-terminal EGFP tag (Fig-
ure S3). MM2-EGFP levels in whole brain are slightly higher
than WT-EGFP and untagged WT protein by both western blot-
ting and flow cytometry (116% of WT-EGFP; Figures 3A and
S4A). To determine the binding specificity of MM2-EGFP in vivo,
we used ATAC-seq footprinting of hypothalamus (see Figures
1D–1F) by dividing the ATAC-seq profiles for MM2-EGFP by
the equivalent Mecp2 null (KO) data. A footprint was detected
at mCG sites but not at mCAC or mCAT sites (Figures 3B–3D).
There was also no MM2-EGFP binding at methylated motifs
that MeCP2 cannot recognize (mCAG, mCT, or mCC) or at un-
methylated motifs (Figures 3B–3D and S4B–S4F). Therefore,
the binding specificity of the chimeric protein is restricted to
mCG sites in vivo, consistent with the in vitro data (Figure 2D).
Compared to WT protein, MM2-EGFP had a lower affinity for
mCG in EMSA and FRAP (Figures 2D and 2F), yet the similarD2 in the context of MeCP2
ed by percentage identity, with conservation below. Annotations: RTT-causing
111 in MeCP2 (boxed in red); sequences from mMeCP2 and mMBD2 used in
f MBD2 (residues 153–217) was inserted into the MeCP2 protein sequence to
inus with EGFP.
ontaining a single unmethylated or methylated CG, CAC, or CAT site. Quanti-
P2 andMM2 using DNA probes containing a single mCG ormCAC site (protein
g affinity was compared using 2-way ANOVA: WT mCG versus mCAC, NS p =
nd MM2 proteins to mCG-rich heterochromatic foci following transient over-
nt mutation in MM2) abolished binding, resulting in diffuse localization. Scale
GFP, n = 27; MM2-EGFP, n = 28 (3 independent transfections). Graph shows
66 ± 2.32 s; MM2-EGFP = 20.46 ± 2.88 s (means ± SEMs). Half-lives were
A B C
D
F
E
(legend on next page)
ll
OPEN ACCESSArticle
Molecular Cell 81, 1260–1275, March 18, 2021 1265
ll
OPEN ACCESS Articleappearance of ATAC-seq footprints (Figures 1D and 3B) sug-
gested similar occupancy of these sites in vivo. To address this
further, we normalized the MM2-EGFP ATAC-seq profile to WT
instead of KO profiles. As expected, if occupancy is approxi-
mately equivalent, this almost canceled out the signals, leaving
a barely discernible footprint at mCG. The weak residual MM2-
EGFP/WT footprint implies that MM2-EGFP is slightly more en-
riched than WT at mCG motifs, perhaps due to the availability
of extra MM2-EGFP molecules that would otherwise be seques-
tered at mCAC sites. Efficient binding of MM2-EGFP to mCG
in vivowas further evidenced by its colocalization to heterochro-
matic foci in the brains of the knockin mice (Figure 3F). This did
not appear to affect the structure of heterochromatin as the num-
ber and size of DAPI foci was unchanged (Figure S4F). In addition
to its DNA binding properties, we used IP to confirm that MM2-
EGFP retains the ability to bind members of the NCOR1/2 co-
repressor complex in brain tissue (Figure S4G). These results
show that the MBD domain swap has uncoupled the DNA bind-
ing specificities of MeCP2, abolishing its interaction with sites of
non-CG methylation in the brain.
MM2 knockin mice display an RTT-like phenotype
To determine the phenotypic consequences of the domain
swap, we assessed weekly a cohort of hemizygous male
MM2-EGFP mice and WT littermate controls (n = 10 per geno-
type) for overt symptoms associated with mouse models of
RTT: hypoactivity, abnormal gait, hind-limb clasping, tremor,
irregular breathing, and deterioration of general condition (Guy
et al., 2007). Like mice with RTT-causing mutations, MM2-
EGFP mice were born healthy and the onset of symptoms
occurred shortly after weaning (Figure 4A). The phenotypes
became progressively more severe until animals reached their
humane endpoint, with a median survival of 29.5 weeks (Fig-
ure 4B). MM2-EGFP mice weighed less than WT littermates
throughout their lifetime (Figure 4C), consistent with RTT models
on a C57BL/6J background (Brown et al., 2016; Guy et al., 2001).
In addition, acute loss of body weight, which accompanies se-
vere disease in RTT models, was correlated with morbidity in
theMM2-EGFP mice. Mouse models of RTT vary in severity de-
pending on MeCP2 mutation, mirroring trends observed in hu-
man patients (Brown et al., 2016; Cuddapah et al., 2014).
MM2-EGFP mice lie in the middle of the RTT severity spectrum,
closely following the progression seen in R306C-EGFP mutant
mice (Figures 4D–4F). More detailed analysis of the six overt
symptoms that were scored weekly revealed that with the
exception of tremors, MM2-EGFP mice recapitulated the RTT
phenotypic signature (Figure 4G). This was most obvious whenFigure 3. MM2 binds mCG but not mCAC or mCAT in vivo
(A) Flow cytometry analysis of protein levels in nuclei fromwhole brain (All) and the
detected using EGFP fluorescence. Graph shows means ± SEMs, and genotype
EGFP, *p = 0.030; Neurons: 116% ± 0.01% of WT-EGFP, *p = 0.018; au, arbitra
(B–D) ATAC-seq footprinting analysis of MM2-EGFP over methylated (top) and u
thalamus. Equivalent WT ATAC-seq footprinting is shown in Figures 1D–1F.
(E) Direct comparison of ATAC-seq profiles over mCG sites between MM2-EGFP
(F) WT-EGFP and MM2-EGFP are both localized at mCG-rich pericentromeric
dentate gyrus of the hippocampus). WT-EGFP and MM2-EGFP were visualized b
NeuN staining shows neuronal nuclei. Scale bar, 10 mm.
1266 Molecular Cell 81, 1260–1275, March 18, 2021phenotypic severity scores of MM2-EGFP, R306C-EGFP, and
R133C-EGFPmice were aligned to focus on the 5 weeks before
reaching their humane endpoint (Figure 4H).
A second cohort ofMM2-EGFPmale mice and WT littermates
(n = 10 per genotype) underwent a series of behavioral tests at
10–11 weeks of age. Like RTT models (Brown et al., 2016),
MM2-EGFP mice displayed decreased anxiety in the elevated
plus maze, spending significantly more time in the open arms
than WT littermate controls (Figure 5A). MM2 mice were slightly
hyperactive in the open field test (Figure 5B), which differs from
the reduced activity characteristic of RTT models. However,
both MM2-EGFP and RTT models displayed progressive loss
of spontaneous activity as phenotypes worsened (Figures 4G
and 4H).MM2-EGFPmice exhibited a trend toward reducedmo-
tor coordination in the hanging wire test (Figure 5C). Motor func-
tion was better assessed by the accelerating rotarod, in which
WT mice showed an increasing ability to stay on the rotarod
over the 3 days, but the MM2-EGFP mice had significantly
impaired performance compared to the controls on days 2 and
3 (Figure 5D). The poor performance of the MM2-EGFP mice is
due to exercise fatigue (Figure S5), in addition to lack of motor
learning. Motor deficits are observed in all mouse models of
RTT (Brown et al., 2016; Goffin et al., 2011; Tillotson and Bird,
2019). In summary, MM2-EGFP mice share most of the pheno-
typic features found in mice that are deficient in functional
MeCP2, including delayed symptom onset, hind limb clasping,
motor defects, decreased anxiety, and premature death.
MM2 represses transcription at mCG but not
mCAC sites
Global transcriptional changes caused by the deficiency of func-
tional MeCP2 are thought to underlie RTT (Chahrour et al., 2008;
Chen et al., 2015; Gabel et al., 2015; Kinde et al., 2016; Lagger et
al., 2017; Renthal et al., 2018). However, the relative contribution
of mCG andmCAC to MeCP2-dependent transcriptional regula-
tion is not known. To address this, we performed RNA-seq using
hypothalamus isolated from Mecp2 null (KO) and WT littermate
controls at 6 weeks of age, when KO mice are symptomatic
but have not reached their humane endpoint. For comparison,
we harvested tissue from MM2-EGFP mice and WT littermate
controls at 2 time points: 6 weeks (age matched with KO) and
12 weeks (when the phenotypes of the 2 mutants are approxi-
mately similar). As shown previously (Kinde et al., 2016), gene
expression changes in KO compared to WT controls are posi-
tively correlated with the total number of MeCP2 binding sites
(mCG + mCAC) in gene bodies (Figure 6A). Plotting these tran-
scriptional changes against each motif separately appears tohigh-NeuN subpopulation (Neurons) inWT-EGFP (n = 3) andMM2-EGFP (n = 3),
s were compared by t tests. All: MM2-EGFP levels are 116% ± 0.03% of WT-
ry units.
nmethylated (bottom) CG (B), CAC (C), and CAT (D) sites in the mouse hypo-
and WT samples.
heterochromatin in the brains of knockin mice (representative images of the
y EGFP fluorescence, heterochromatic foci appear as DAPI bright spots, and
A B C
D E F
G H
Figure 4. MM2 knockin mice display overt RTT-like neurological defects
(A) Phenotypic severity scores of hemizygous male MM2-EGFP mice (n = 10) compared with their WT littermates (n = 10) over 1 year. Graph shows mean
scores ± SEMs.
(B) Kaplan-Meier plot of survival of the scoring cohort. TwoWT controls were culled due to injuries, aged 38 and 45weeks (censored). Genotypes were compared
using a Mantel-Cox test: ****p < 0.0001.
(C) Growth curve of the scoring cohort. Graph shows mean values ± SEMs. Genotypes were compared using mixed-effects analysis: ****p < 0.0001.
(D–F) Phenotypic severity score (D), survival (E), and growth curves (F) ofMM2-EGFPmice over 1 year compared toMecp2 null mice (n = 12/24/20) and models
carrying patient mutations: T158M-EGFP (n = 7/11/15), R306C-EGFP (n = 11), and R133C-EGFP (n = 10) (Brown et al., 2016).
(G and H) Heatmaps of the phenotypic scores ofMM2-EGFP, R306C-EGFP, and R133C-EGFPmice shown in (D), divided into the 6 categories. Plots are shaded
according to the mean score for each category. Scores were analyzed according to age (G) and for the 5 weeks before each mouse reaches its humane endpoint
(H). Weeks in which mice were not assessed are marked with an X.
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KOmice, as expected (Figures 6B and 6C), but the strong corre-
lation between the number of mCG and mCAC sites in genes
(Figure 6D; r = 0.90) means that this analysis with respect to
one motif will also be substantially influenced by the other motif.
This could account for the positive trends observed between
MM2-EGFP/WT transcriptional changes and both mCG andmCAC abundance (Figures 6E–6G and S6A–S6C), despite the
predicted loss of only mCAC-dependent repression in MM2-
EGFP mice.
To distinguish the effects of the two motifs, we binned genes
according to the number of mCAC sites per transcription unit
to determine the effect of mCG (Figure S6D). In all of the bins
except the first and last, the low variation in mCAC level butMolecular Cell 81, 1260–1275, March 18, 2021 1267
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Figure 5. MM2 knockin mice display behavioral defects associated
with the RTT-like phenotype
(A–D) Behavioral analysis of a separate cohort performed at 10–11 weeks of
age:MM2-EGFP (n = 10), compared with their WT littermates (n = 10). Graphs
show individual values andmedians, and statistical significance as follows: NS
p > 0.05, *p < 0.05, **p < 0.01.
(A) Time spent in the closed and open arms of the elevated plus maze. Ge-
notypes were compared using Kolmogorov-Smirnov (KS) tests: closed arms,
*p = 0.015; open arms, **p = 0.003.
(B) Distance traveled in open field test. Genotypes were compared using a t
test: *p = 0.022.
(C) Mean time taken for animals to bring a hind paw to the wire in the hanging
wire test in 3 trials (each up to 30 s). Genotypes were compared using a KS
test: p = 0.055.
(D) Mean latency to fall from the accelerating rotarod in 4 trials was calculated
for each of the 3 days of the experiment. Genotypes were compared using KS
tests: day 1, p = 0.401; day 2, *p = 0.015; and day 3, *p = 0.015. WT animals
displayed significant improvement over the 3 days (*p = 0.026); MM2-EGFP
animals did not change significantly (p = 0.314); analyzed with Friedman tests.
ll
OPEN ACCESS Articlehigh variation in mCG across the constituent genes enabled the
assessment of mCG-dependent repression. We therefore used
bins nos. 2–28 for this analysis. We similarly binned by mCG
number to assess mCAC-dependent repression (Figures S6D–
S6G). Methylation levels in each bin were plotted against log2-
fold changes in KO/WT or MM2-EGFP/WT to give a line whose
slope reflects the effect of mCG or mCAC on transcription (Fig-
ures 6H and 6I). Applying this first to KO mouse hypothalamus,
we observed the loss of mCG-dependent repression (slopes
above zero) compared to WT controls (Figure 6H; Table S1) in
bins with lower levels of methylation, exemplified by the bin1268 Molecular Cell 81, 1260–1275, March 18, 2021with an average of log10 1.32mCACmotifs (denoted by #). Genes
with higher mCAC levels showed no evidence of repression
(example bin denoted by x), indicating that mCG-dependent
repression is minimal where mCAC is relatively abundant. In
contrast, mCAC-dependent repression was restricted to bins
with higher mCG (Figure 6I; Table S2), as exemplified by the
bin with an average of log10 3.08 mCG motifs per gene (denoted
by z), whereas at lower mCG levels, mCAC-dependent repres-
sion was not apparent (example bin denoted by z). In line with
this interpretation, the proportion of all binding sites that are
mCG is higher in bins showing mCG-dependent repression (Fig-
ure 6J), while the proportion of mCAC binding sites is highest in
bins showing mCAC-dependent repression (Figure 6K).
Having separated the effects of mCG and mCAC in the com-
plete absence of MeCP2, we next performed this analysis on
transcriptional changes in MM2-EGFP mice compared to 6-
week-old WT controls. The profile of mCAC-dependent tran-
scriptional deregulation closely tracked that of KO/WT profiles
across mCG bins, consistent with the absence of mCAC-medi-
ated repression in both mutants (Figure 6I; Table S2). However,
the profile of mCG-dependent deregulation differed from that
seen in KO/WT. As expected, if mCG-dependent repression is
preserved in MM2-EGFP mice, the positive slope observed for
KO/WT in bins with lower levels of mCAC was lost in MM2-
EGFP/WT (slopes of 0), (Figure 6H, example bin #; Table S1).
We noted that in bins with higher mCAC methylation, transcrip-
tional changes were negatively correlated with the number of
mCG binding sites, suggesting somewhat increased mCG-
dependent repression of these genes in MM2-EGFP mice
compared to WT controls. As WT MeCP2 exerts little inhibitory
effect at mCG sites in these high-mCAC genes, this effect may
be due to the slight increase in MM2-EGFP abundance
compared to native protein (Figures 3A and S4A). Also, the
inability of MM2-EGFP to target mCAC may make it more avail-
able for mCG-mediated repression. This effect is not sufficient to
prevent the upregulation of the highly methylated genes, howev-
er, as the primary driver of their repression is normally mCAC,
which MM2-EGFP does not recognize. These results were repli-
cated in the hypothalamus tissue harvested at 12 weeks (Figures
S6H and S6I). In summary, the evidence demonstrates that
MM2-EGFP protein has specifically lost the ability to repress
the transcription at mCAC sites, disproportionally affecting
genes with higher levels of methylation. This implicates loss of
mCAC-dependent repression as the primary cause of the severe
RTT-like phenotypes that we observe in MM2-EGFP mice.
Shared dysregulated genes are implicated in disease
RTT may be caused by the aggregate effect of small transcrip-
tional changes at hundreds of genes. Alternatively, a few dysre-
gulated genes may be primarily responsible for the phenotypes,
the remainder being relatively neutral. Given the remarkable sim-
ilarity between the phenotypes of MM2-EGFP and RTT mice,
these genes are expected to be affected in both mutants. Signif-
icantly changed genes overlapped by approximately one-third in
both the age-matched and symptom-matched datasets (Fig-
ure 7A, purple shading). Importantly, for almost all of the 316
shared genes, the direction of transcriptional change was the
same in KO and MM2-EGFP mice (Figures 7B and S7A). To
(legend on next page)
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candidates whose altered expression contributes strongly to
the RTT phenotype, we performed Disease Ontology analysis
on each of the three groups: shared (purple), KO only (gray),
and MM2-EGFP only (orange). We found that the shared genes
were enriched in genes associated with four categories of neuro-
logical disease: ‘‘pervasive developmental disorder,’’ ‘‘autism
spectrum disorder,’’ ‘‘autistic disorder,’’ and ‘‘developmental
disorder of mental health’’ (Table S3). It is notable that the
same analysis on genes dysregulated only in KO mice or only
in MM2-EGFP mice gave no significant disease hits. There was
a strong overlap between the four neurological disease cate-
gories, with all 20 genes associated with developmental disorder
of mental health present in one or more of the other categories.
The candidate genes were similarly dysregulated in both mu-
tants in this study and an independent hypothalamus dataset
(Figure 7C) (Chen et al., 2015). Many of these genes were also
dysregulated in KO cortical tissue (Figure 7C) (Boxer et al.,
2019), suggesting consistency between different regions of the
RTT brain.
Differential gene expression could contribute to the disease
state regardless of the direction of change, but 15 of 20 candi-
date genes were upregulated in both mutants (Figure 7C), sug-
gesting that they are direct MeCP2 targets. Comparisons be-
tween all of the shared dysregulated genes and those affected
in KO orMM2-EGFP only or unaffected in either mutant showed
that shared genes had the highest number of methylated binding
sites (mCG + mCAC) (Figures 7D and S7B), highest mCAC:total
ratios (Figures 7E and S7C), and tended to be more highly upre-
gulated (Figures 7F and S7D). Interestingly, the 20 candidate
genes have exceptionally high levels of methylation, proportion
of mCAC sites, and transcriptional upregulation (Figures 7D–7F
and S7B–S7D). These genes represent strong candidates for
future investigation as their dysregulationmay contribute dispro-
portionately to the neurological features of RTT.
DISCUSSION
This study investigated the biological significance of the dual-
binding specificity of MeCP2. MBD functionality is essential for
the role of MeCP2 protein, but as RTT-causing missense muta-
tions in this domain disrupt bothmCGandmCACbinding (Brown
et al., 2016), the importance of its ability to target mCAC sites
was previously unknown. Our results show that mice dependent
on a derivative of MeCP2 (MM2) that can bind mCG but not
mCAC develop severe RTT-like symptoms. We note that MM2Figure 6. MM2 represses transcription at mCG but not mCAC sites
(A–C and E–G) Correlations between the total number of MeCP2 binding sites p
scriptional changes in KO/WT (A–C) and MM2-EGFP/WT (E–G) hypothalamus tis
(D) Correlation between mCG and mCAC binding sites per gene in the hypothala
(E–G) Correlations between MeCP2 binding sites and transcriptional changes in
(H) Genes were binned by the number of mCAC binding sites to determine the e
example bins are shown (# bin 12, mean log10 mCAC = 1.32; and x bin 25, mean l
shown below. See Table S1.
(I) Genes were binned by the number of mCG binding sites to determine the effec
mCG = 2.12; and z bin 27, mean log10 mCAC = 3.08). The slopes (±95% confide
(J) The ratio of mCG/total binding sites per gene in each mCAC bin.
(K) The ratio of mCAC/total binding sites per gene in each mCG bin. Whiskers sh
1270 Molecular Cell 81, 1260–1275, March 18, 2021protein is slightly more abundant (1.16-fold) and has altered
mCG binding dynamics, compared to native MeCP2. However,
these differences are quite modest and are therefore likely to
have minimal phenotypic consequences. For comparison, 2-
fold overexpression ofWTMeCP2 results in neurological defects
that are considerably milder than RTT models (Collins et al.,
2004). Despite the reduced affinity for mCG in the in vitro and
cell-based assays (Figures 2D and 2F), MM2-EGFP occupies
mCG sites in the brain at least as highly as WT protein (Figures
3E and 3F). We therefore conclude that the ability of MeCP2 to
target mCAC is essential to avoid the neurological problems
associated with RTT and cannot be compensated for by binding
to mCG alone.
The deposition and interpretation of non-CG
methylation is essential for neurological function
Previous studies have investigated whether loss of the mCAC
writer DNMT3A has similar consequences to loss of the reader
MeCP2 (Gabel et al., 2015; Lavery et al., 2020; Stroud et al.,
2017). Although DNMT3A preferentially methylates CG over
CH (Ramsahoye et al., 2000), its expression in postnatal neu-
rons, particularly during the first 3 weeks of life (Feng et al.,
2005), mainly leads to mCH (predominantly mCAC) deposition,
as the majority of CG dinucleotides have already been methyl-
ated in early development (Lavery et al., 2020; Stroud et al.,
2017). The difference in timing means that writing of these marks
can be uncoupled by Cre-mediated deletion of Dnmt3a after the
early embryonic deposition of mCG but before the postnatal
deposition of mCH. Accordingly, the deletion of Dnmt3a in the
central nervous system (CNS) between embryonic day (E) 7.5
and E15.5 using Nestin-Cre abolishes mCH in the brain with a
much lower impact on mCG (Dubois et al., 2006; Gabel et al.,
2015). These mice display neurological defects, including hypo-
activity, hind limb clasping, and gait and motor defects, resulting
in premature death at 18 weeks of age (Nguyen et al., 2007;
Stroud et al., 2017). The strong overlap with the RTT phenotype
is consistent with the interpretation of this mark by MeCP2. At
the molecular level, loss of either DNMT3A or MeCP2 results in
overlapping transcriptional changes (Gabel et al., 2015; Lavery
et al., 2020). Our MM2 mice build on this evidence by showing
that specifically abolishing the ability of MeCP2 to read mCH is
sufficient to cause many of the neurological defects and tran-
scriptional changes associated with the RTT phenotype.
It has been speculated that the postnatal deposition of mCH
could explain the delayed onset of the RTT phenotype (Chen
et al., 2015; Lavery et al., 2020), implying that MeCP2 bindinger gene (between TSS and TTS): mCG + mCAC, mCG, and mCAC and tran-
sue at 6 weeks of age.
mus at 6 weeks. Regression (r) = 0.90.
MM2-EGFP/WT.
ffect of mCG on transcription in KO/WT and MM2-EGFP/WT (6 weeks). Two
og10 mCAC = 2.34). The slopes (±95% confidence interval) of all of the bins are
t of mCAC on transcription. Two example bins are shown (z bin 11, mean log10
nce interval) of all of the bins are shown below. See Table S2.
ow 5th–95th percentiles.
A
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Figure 7. Shared dysregulated genes are
linked to neurological disease
(A) Venn diagram showing the overlap between
significantly dysregulated genes in KO (6 weeks),
MM2-EGFP (6 weeks), andMM2-EGFP (12 weeks),
each compared to age-matched WT controls. Sig-
nificance cutoff: adjusted p (padj) < 0.05.
(B) Shared genes are dysregulated in the same di-
rection in KO/WT (6 weeks) and MM2-EGFP/WT
(12 weeks).
(C) Heatmap showing transcriptional changes in the
20 neurological disease-associated genes. The 3
datasets in this study were compared to an inde-
pendent KO/WT (6 weeks) hypothalamus dataset
(Chen et al., 2015) and a KO/WT (8 weeks) cortex
dataset (Boxer et al., 2019). Avpr1a is not ex-
pressed in cortex (X).
(D) Comparison of mCG + mCAC binding sites be-
tween unchanged genes, and dysregulated genes
in KO only, MM2-EGFP only, both mutants and
disease-associated genes.
(E) Ratios of mCAC to total binding sites in these
gene categories.
(F) Expression changes in KO/WT andMM2-EGFP/
WT in these gene categories. Black bars show
median values; whiskers show 5th–95th percen-
tiles. Pairs of gene sets were compared using
Mann-Whitney tests: ***p < 0.001, ****p < 0.0001.
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ing is largely dispensable in early development (before symptom
onset at weaning) and at all developmental stages in peripheral
tissues where only mCG sites are available (Guy et al., 2001;
Ross et al., 2016). In neurons, however, MeCP2 levels are
much higher than any other cell type, plateauing at 5 weeks
of age at a level that allows MeCP2 to coat neuronal chromatin
(Skene et al., 2010). In the absence of any evidence that
MeCP2 interprets mCG and mCAC sites differently, the relative
importance of these two motifs likely depends on their abun-
dance and location. Considering first abundance, in mature neu-
rons, the evidence suggests that mCG and mCH binding sites
occur with approximately equal frequencies (Mo et al., 2015). It
is therefore possible that the accumulation of mCAC simply in-
creases the number of available MeCP2 binding sites. If so,
then replacing MeCP2 with MM2, which retains the ability to
confer transcriptional repression at more than half of the
MeCP2 binding sites, would be equivalent to halving MeCP2
protein levels. Our findings rule out this possibility, as mice ex-
pressing MeCP2 at 50% normal levels display only very mildMoleculabehavioral phenotypes (Samaco et al.,
2008), compared with the severe RTT-
like symptoms seen in MM2-EGFP mice.
It is therefore likely that differences in
the patterning of mCG and mCAC sites
underlie their distinct functional signifi-
cance. CG dinucleotides are globally
depleted in the genome, but highly meth-
ylated from an early stage of develop-
ment. This means that the number of
mCGs per gene approaches the numberof CG dinucleotides and is relatively uniform between cell
types. In contrast, the number of CH motifs is more than an or-
der of magnitude higher than CG, but they become sparsely
methylated in neurons (predominantly at CAC) after mCG pat-
terns have already been laid down. Importantly, the application
of mCAC methylation is not uniform, but targets genes in in-
verse proportion to their expression level during the early post-
natal period (Stroud et al., 2017). We show here that, on
average, highly methylated genes acquire a greater proportion
of mCAC motifs, so they are disproportionally affected by
mCAC-dependant repression by MeCP2. Loss of mCAC-
dependent repression results in their upregulation in both
Mecp2 null and MM2-EGFP mice, suggesting that their dysre-
gulation contributes substantially to neurological defects. Pat-
terns of mCAC methylation have also been reported to be
more cell type specific as a result of differences in expression
during its deposition (Mo et al., 2015; Stroud et al., 2017).
Future work will address the roles of neuronal subtype-specific
patterns of mCAC-dependent transcriptional modulation of
highly methylated genes for maintaining brain function.r Cell 81, 1260–1275, March 18, 2021 1271
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symptoms
Since the discovery that MeCP2 controls transcription, the RTT
field has searched for key target genes. While some genes
(e.g., Bdnf) have been shown to have larger effects (Chang
et al., 2006), the preferred view is that the neurological condi-
tion is an aggregate consequence of subtle changes in hun-
dreds of genes. In addition, many of these genes are downre-
gulated, a likely consequence of smaller cell size (Lagger et al.,
2017; Li et al., 2013; Yazdani et al., 2012). In this study, we
focused on genes dysregulated in both mutants, given their
overlapping phenotypes. This list comprises one-third of the
genes altered in Mecp2 null mice (n = 316), which tend to be
highly methylated and therefore direct MeCP2 targets. Of the
20 candidates identified by Disease Ontology analysis, 15
were markedly upregulated in both mutants. Neurological dis-
ease is often linked with haploinsufficiency of these genes,
raising the possibility that dosage may be critical, with their
overexpression also being deleterious, as is the case for
MECP2 (Van Esch et al., 2005). Genes implicated in neurolog-
ical disease typically encode proteins falling into two cate-
gories: those with specific roles in neuronal function and chro-
matin-associated factors. The candidates identified in this
study span both classes. For example, CNTN4 is a neuronal
membrane glycoprotein (Oguro-Ando et al., 2017) and AUTS2
activates transcription in association with non-canonical
PRC1 (Gao et al., 2014). Time will tell whether the dysregulation
of these candidates is involved in RTT pathology and whether
any could be targeted therapeutically.
Concluding remarks
It is interesting to speculate on the origin of the dual-binding
specificity of MeCP2. There is evidence that MeCP2 originally
evolved as a mCG-specific DNA binding protein (Hendrich and
Tweedie, 2003), as other members of the MBD protein family
cannot bind to mCH (Guo et al., 2014; Liu et al., 2018). We sug-
gest that during the course of evolution, MeCP2 has added to its
repertoire the ability to bindmCAC due to the relative flexibility of
the side chain of arginine 133, which is one of a pair of key argi-
nines involved in DNA recognition (Ho et al., 2008; Lagger et al.,
2017; Lei et al., 2019). In contrast, the equivalent arginine side
chain in MBD2 is constrained by interactions with other parts
of the protein (Liu et al., 2018; Scarsdale et al., 2011). According
to this view, the coevolution of DNMT3A and MeCP2 has turned
two somewhat peripheral, perhaps originally biologically unim-
portant, properties of each protein (mCAC methylation and
mCAC binding, respectively) into essential contributors to brain
stability and function (see Bird, 2020).
Limitations
Experiments designed to distinguish alternative explanations for
our findings are presented throughout. MM2 is a hybrid protein in
which the native DNA binding domain has been replaced by a
related sequence that we show in vivo and in vitro binds only
one of the twoMeCP2 target motifs. Our hope that mCG binding
by MM2 would resemble mCG binding by native MeCP2 was
broadly supported by the evidence, but it remains possible
that a component of the deleterious phenotype in mice is due1272 Molecular Cell 81, 1260–1275, March 18, 2021to differences in mCG binding affinity. We explain in the first
paragraph of the Discussion why any effect on the interaction
with mCG is likely to be minor; hence our conclusion that failure
to bind mCAC is primarily responsible for the RTT-like defects.
The list of genes that we implicate in RTT relies on evidence
that the phenotypes of MM2-EGFP and Mecp2 null male mice
have the same root cause. Despite their impressive credentials
as MeCP2 target genes (high levels of DNA methylation; unusu-
ally strong upregulation in both mutants), their contributions to
the RTT phenotype are so far untested and will be the subject
of future work.STAR+METHODS
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Materials availability
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Data and code availability
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial strains
BL21(DE3)RIPL competent cells (Agilent) were used to express MeCP2[MBD].
BL21(DE3)-R3-pRARE2 competent cells (Savitsky et al., 2010) were used to express MBD2[MBD].
BL21(DE3)pLysS competent cells (Promega) were used to express MeCP2[N-term] and MM2[N-term].
Cell lines
HeLa and NIH 3T3 (ATCC, RRID:CVCL_0594) cells were grown in DMEM (GIBCO) supplemented with 10% fetal bovine serum (FBS;
GIBCO) and 1%penicillin– streptomycin (GIBCO). Low passagemale E14 TG2a ES cells (derived from 129/Ola mice) were a gift from
AndrewSmith at the Centre for GenomeResearch at the University of Edinburgh (now Institute for StemCell Research). ES cells were
grown in Glasgow MEM (GIBCO) supplemented with 10% FBS (GIBCO, batch tested), 1% non-essential amino acids (GIBCO), 1%
sodium pyruvate (GIBCO), 0.1% b -mercaptoethanol (GIBCO) and 1,000 units/ml LIF (ESGRO). Mouse ES cell status was confirmed
regularly by production of germline chimeric mice from the cells (e.g., Tillotson et al., 2017). All cells were grown at 37C, 5% CO2.
Mouse lines
All mice used in this study were bred and maintained at the University of Edinburgh animal facilities under standard conditions, and
procedures were carried out by staff licensed by the UK Home Office and in accordance with the Animal and Scientific Procedures
Act 1986. All mice were housed in a specific-pathogen-free (SPF) facility. They were maintained on a 12-h light/dark cycle and given
ad libitum access to food (RM1 or RM3) and water. They were housed in open top cages with wood chippings, tissue bedding and
additional environmental enrichment in groups of up to ten animals. Mutant mice were caged with their wild-type littermates.
MM2-EGFPmice were generated in this study from edited ES cells (detailed method described below). The edited allele contained
a floxed selection cassette, which was removed by breeding chimeras with CMV-Cre deleter mice (C57BL/6J- Tg(CMV-cre)1Cgn,
RRID: IMSR_JAX:006054). This line was further backcrossed onto C57BL/6J to N4 before behavioral phenotyping and to at least
N4 for biochemical analysis. Hemizygous MM2-EGFP males (and wild-type controls) were used in all experiments as symptoms
develop earlier and progress more rapidly than heterozygous females (as with otherMecp2mutant mice). To produce behavioral co-
horts, male pups from timed matings were pooled at weaning and randomly assigned to the two groups. The first cohort was moni-
tored for overt RTT-like symptoms, weight and survival from four weeks of age until each animal’s humane end-point (wild-type con-
trols were monitored to one year of age). The second cohort underwent behavioral testing at 10-11 weeks of age. Tissues for
biochemical analysis were harvested from animals at 6-19 weeks of age.Molecular Cell 81, 1260–1275.e1–e12, March 18, 2021 e4
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controls in some biochemical assays. They were maintained on a C57BL/6J background.
Mecp2 null mice (C57BL/6J;CBA/CA-Mecp2tm2Bird, RRID: IMSR_JAX:006849) mice (Guy et al., 2001) were used for ATAC-seq
analysis to determine the footprints of wild-typeMeCP2 andMM2-EGFP and for RNA-seq analysis. Theyweremaintained on amixed
C57BL/6J;CBA/CA background, as breeding difficulties occur after backcrossing onto a C57BL/6J background. Hypothalamus tis-
sue was harvested at 6 weeks of age.
Phenotypic data was compared to RTT models: Mecp2 null mice (C57BL/6J-Mecp2tm2Bird, RRID: IMSR_JAX:006849), T158M-
EGFP (C57BL/6J-Mecp2tm4.1Bird, RRID:IMSR_JAX:026762), R306C-EGFP (C57BL/6J-Mecp2tm5.1Bird, RRID:IMSR_JAX:026847)
and R133C-EGFP (C57BL/6J-Mecp2tm6.1Bird, RRID:IMSR_JAX:026848). This data was previously published in Brown et al. (2016).
METHOD DETAILS
Design of MM2
According to convention, all amino-acid numbers given refer to the e2 isoform. Numbers refer to homologous amino acids in human
(NCBI accession P51608) and mouse (NCBI accession Q9Z2D6) protein, until residue 385 where there is a two-amino-acid insertion
in the human protein. In this study, the MBD of mouseMeCP2was defined as residues 94-164. This region was replaced by theMBD
of mouse MBD2 (NCBI accession Q9Z2E1), comprising residues 153-217. Note: the region of MeCP2 replaced was shorter than the
minimal fragment required for binding to methylated DNA (Nan et al., 1993). This region comprises the highly conserved sequence
among MBD family members and contains all RTT-causing missense mutations in the MBD cluster, listed on RettBASE: http://
mecp2.chw.edu.au/ (Krishnaraj et al., 2017). The region is flanked by proline residues (disrupting protein structure), which were
selected as the junctions in MM2 (P93 and P165 of MeCP2). This protein was tagged at the C terminus by EGFP, connected by a
short linker. To be consistent with the WT-EGFP mice (Brown et al., 2016), the linker sequence was CKDPPVAT (DNA sequence:
TGTAAGGATCCACCGGTCGCCACC). Intron 3 (located in theMBD ofMeCP2) was not inserted intoMM2 as it was deemed dispens-
able due to poor evolutionary conservation.
Plasmids
For expression of MeCP2[MBD] in bacteria, cDNA encoding MeCP2 (residues 77-167) was cloned into pET28 using NdeI and EcoRI
restriction sites. The protein sequence of this fragment is identical in human and mouse.
For expression of MBD2[MBD] in bacteria, cDNA encoding human MBD2 (residues 139-224, NCBI accession number
NP_003918.1, from the Mammalian Gene Collection: BC032638.1, IMAGE: 5496721) was amplified by polymerase chain reaction
(PCR) (primer sequences in Table S4) in the presence of Herculase II fusion DNA polymerase (Agilent Technologies). PCR products
were purified (QIAquick PCR Purification Kit, QIAGEN UK) and further sub-cloned into a pET28-derived expression vector, pNIC28-
Bsa4 using ligation-independent cloning (Savitsky et al., 2010). This vector includes sites for ligation-independent cloning and a To-
bacco Etch Virus (TEV)-cleavable N-terminal His6-tag (extension MHHHHHHSSGVDLGTENLYFQ*SM-). After digestion with TEV
protease, the protein retains an additional serine and methionine on the N terminus. The construct was transformed into competent
Mach1 cells (Invitrogen, UK) to yield the final plasmid DNA.
For expression of MeCP2WT and derivatives in mammalian cells, plasmids expressing EGFP-tagged e2 isoforms were used. Pre-
viously published (Tillotson et al., 2017) plasmids were used to express WT (RRID: Addgene_110186), R111G (RRID: Addg-
ene_110187) and R306C (RRID: Addgene_110188). To clone MM2, the MBD of MBD2 and flanking MeCP2 sequences was synthe-
sized (GeneStrings, Thermo Fisher Scientific; sequence in Key resources table) and cloned into the pEGFP-N1_MeCP2[WT] plasmid
to replace theMeCP2MBD sequence using PstI restriction sites (NEB). R169Gwas inserted into theMM2 vector using aQuikChange
II XL Site-Directed Mutagenesis Kit (Agilent Technologies) (primer sequences in Table S4). pmCherry-N1_TBL1X (Lyst et al., 2013)
was used in the recruitment assay. For expression of MeCP2[N-term] and MM2[N-term] in bacteria for protein production, residues
1-205 of MeCP2 and the equivalent fragment of MM2 were subcloned from the pEGFP-N1 vectors into pET30b (Novagen). The for-
ward primer introduced a NdeI restriction site and the reverse primer introduced a C-terminal 6xHis tag and EcoRI site (primer se-
quences in Table S4). To overcome low efficiency, the fragments were blunt cloned into pCR4 using the Zero Blunt TOPO kit (Invi-
trogen) before cloning into the pET30b vector using NdeI and EcoRI (NEB).
For targeting the endogenous Mecp2 locus in ES cells, a gene-targeting construct containing exons 3 and 4 of wild-type MeCP2
with a C-terminal tag (Tillotson et al., 2017) was edited by recombineering. The MBD region was first replaced by the counter-selec-
tion rpsL-neo cassette amplified by PCR to give 50 nt homology arms (primer sequences in Table S4). Positive clones were selected
by kanamycin resistance. This cassette was subsequently replaced by the MBD of MBD2 flanked by MeCP2 sequences amplified
from pEGFP-N1_MM2 (primer sequences in Table S4). Positive clones were selected by Streptomycin resistance and sequence veri-
fied. CRISPR– Cas9 technology was used to increase the targeting efficiency: the guide RNA sequence (GGTTGTGACCCGCCATG-
GAT) was cloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 (a gift from F. Zhang; Addgene plasmid 42230 (Cong et al., 2013)).
All plasmids were sequence verified.e5 Molecular Cell 81, 1260–1275.e1–e12, March 18, 2021
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TheMM2-EGFP targeting vector was linearized using NotI (NEB). 129/Ola E14 TG2a ES cells were passaged every two days for one
week and 20x106 cells were collected in 600 mL HBS containing 15 mg linearized targeting vector and 15 mg of the CRISPR/Cas9
plasmid. The cells were electroporated (GenePulser X, Biorad) in a 0.4 cm cuvette at 240 V, 500 mF, N resistance. The guide RNA
targeted intron 2 of the wild-type gene (at the site of the NeoSTOP cassette in the targeting vector). G418-resistant clones with cor-
rect targeting at theMecp2 locus were identified by PCR and Southern blot screening (method described below). PCR screens were
performed using Phusion polymerase (NEB): primer sequences in Table S4. Screening identified one positive clone (5C7), which was
further verified by Sanger sequencing of theMecp2 locus and the top predicted intragenic off-target locus,Dock5 (primer sequences
in Table S4). The cell line was also karyotyped by inducing metaphase arrest by treatment for 3 hours with 0.1 mg/ml colemid (KAR-
YOMAX,GIBCO). Pelleted cells were resuspended in 300 mL growthmedia plus 5mL 0.4% (w/v) KCl and incubated for 10min. 100 mL
fixative (3 parts methanol: 1 part acetic acid) was added and mixed gently. Cells were pellets at 300 g, 5 min and the pellet was re-
suspended in 5 mL fixative and incubated at room temperature for 20 min. Cells were pelleted again and resuspended in 500 mL fixa-
tive. They were dropped onto pre-chilled glass slides from 30 cm and left to dry overnight before mounting with Vectashield con-
taining DAPI (H-1200). Cells were photographed on a Zeiss AxioImager (Carl Zeiss UK, Cambridge) equipped with a Photometrics
Prime sCMOS camera (Teledyne Photometrics) and chromosomes were counted manually using ImageJ (NIH).
Cells from MM2-EGFP clone 5C7 were injected into blastocysts (E3.5) obtained from C57BL/6J females after natural mating. As
with previous studies, e.g., Guy et al. (2001), 15 ES cells were injected into each blastocyst and 12 injected blastocysts were trans-
ferred to pseudo-pregnant recipient females (F1 C57BL/6J;CBA/CA). Chimeric pups were recognized by coat color. This targeted
locus contained a neomycin resistance gene followed by a transcriptional STOP cassette flanked by loxP sites (‘floxed’) in intron
2. This cassette was removed in vivo by crossing chimeras with homozygous females from the transgenic CMV-cre deleter strain
(Tg(CMV-cre)1Cgn, RRID: IMSR_JAX:006054) on a C57BL/6J background. The CMV-cre transgene was subsequently bred out.
Genotyping primers for the Mecp2 locus and Cre transgenes are in Table S4.
Southern blotting
Genomic DNA was purified from ES cells using Puregene Core Kit A (QIAGEN) according to manufacturer’s instructions. Genomic
DNAwas purified from snap-frozen mouse brain (harvested at 7-19 weeks of age) by homogenization in 3 mL lysis buffer (50 mM Tris
HCl pH7.5, 100 mM NaCl, 5 mM EDTA). Proteinase K was added to a final concentration of 0.4 mg/ml and SDS to 1% (w/v). After
overnight incubation at 55C, samples were treated with 0.1 mg/ml RNase at 37C for 1-2 hours and gDNA was extracted with
3 mL PCI (phenol:chloroform:isoamyl alcohol, Sigma). gDNA was precipitated from the aqueous phase with 2.5 volumes 100%
ethanol and 0.1 volumes 3M NaOH, and dissolved in TE. For Southern blotting, 10 mg gDNA was digested with 3 mL enzyme
(NEB) in a total volume of 40 ml, and ran on 0.8% gels. Gels were incubated in 0.25 M HCl (15 min) and neutralised with 0.4 M
NaOH (45 min) before transferring onto ZetaProbe membranes (Biorad). 25 ng of a probe homologous to the 30 homology arm
(1038 pb fragment digested with SpeI and BamHI) was radioactively labeled with [a32]dCTP (Perkin Elmer) using the Prime-a-
Gene Labeling System (Promega) according to manufacturer’s instructions. Membranes were blocked in Church buffer containing
50 mg/ml Herring Sperm DNA (Sigma) at 65C. After 30 min, the probe was added and incubated overnight. Membranes were then
washed three times with 3xSSC/0.2% SDS, followed by up to three washes with 1xSSC/0.2% SDS. The blots were exposed for 1-
5 days on Phosphorimager plates (GE Healthcare) and scanned using a Typhoon FLA 7000. BamHI, BsrGI and KpnI were used to
screen ES cell clones and KpnI was used to verify deletion of the NeoSTOP cassette in MM2-EGFP knock-in mice.
Protein purification
The expression plasmid containingMeCP2[MBD] was transformed into competent BL21 (DE3)-RIPL cells (Life Technologies) and the
MBD2[MBD] plasmid was transformed into competent BL21 (DE3)-R3-pRARE2 cells (a phage-resistant derivative of the BL21 (DE3)
strain), with a pRARE plasmid encoding rare codon tRNAs (Invitrogen). Freshly grown colonies were cultured overnight in lysogeny
broth (LB) supplemented with 50 mg/ml kanamycin and 34 mg/mL chloramphenicol at 37C. One liter of pre-warmed terrific broth
(TB) was inoculated with 10 mL of the overnight culture and incubated at 37C. At an optical density at 600 nm (OD600) of 2.5, the
culture was cooled to 18C and expression was induced overnight at 18Cwith 0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG).
Cells were harvested by centrifugation (8700 x g, 15 min, 4C) in a Beckman Coulter Avanti J-20 XP centrifuge, and then re-sus-
pended in lysis buffer (50 mM HEPES pH 7.5 at 20C, 1500 mM NaCl, 5% Glycerol, 1 mM tris(2-carboxyethyl)phosphine (TCEP)
and 1:1000 (v/v) Protease Inhibitor Cocktail III (Calbiochem)). Cells were lysed using a high-pressure homogenizer (Emulsiflex C5,
Avestin) at 100 mPa equipped with a recirculating cooler (F250, Julabo). DNA was precipitated on ice for 30 min with 0.15% (v/
v) PEI (Polyethyleneimine, Sigma) and the lysate was cleared by centrifugation (16,000 x g for 1 hour at 4C, JA 25.50 rotor, Beckman
Coulter Avanti J-20 XP centrifuge) before being applied to a Nickel affinity column (nickel nitrilotriacetic acid (Ni-NTA) resin, QIAGEN
Ltd., 5 ml, equilibrated with 20 mL lysis buffer). Protein was eluted with an imidazole step gradient (50 to 250 mM) in a 500 mM NaCl
lysis buffer.
For MeCP2[MBD], the eluted protein after Ni-NTA purification was concentrated with 10 kDa MWCO Amicon Ultra (EMD Milli-
pore) concentrators and further purified by size exclusion chromatography on a HiPrep 16/60 Sephacryl S-200 gel filtration column
(GEHealthcare) on an ÄktaPrime plus systems (GE/AmershamBiosciences). ForMBD2[MBD], the eluted protein after Ni-NTA affinity
purification was treated overnight at 4Cwith TEV protease to remove the 63 His tag and untagged proteins were further purified byMolecular Cell 81, 1260–1275.e1–e12, March 18, 2021 e6
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tions were monitored by SDS-PAGE and concentrated in gel filtration buffer (10 mM HEPES pH 7.5, 500 mM NaCl and 5% glycerol)
using Amicon Ultra (EMD Millipore) concentrators with a 10 kDa MWCO cut-off. Proteins were aliquoted, flash frozen in liquid ni-
trogen and stored at 80C until further use.
Expression plasmids containing MeCP2[N-term] and MM2[N-term] with a C-terminal 6xHis tag were transformed into BL21(DE3)
pLysS competent cells and plated. Colonies were scraped into an overnight starter culture in LB with 50 mg/ml kanamycin and 17 mg/
ml chloramphenicol at 37◦C. This was expanded in 500 mL and protein production was induced with 1 mM IPTG at 30◦C for 3 hours
when the OD600 reached 0.6-0.8. Frozen bacterial cell pellets were mashed in 30 mL ice-cold lysis buffer (50 mM NaH2PO4, 100 mM
NaCl, 10% glycerol, 30 mM imidazole, 0.1% NP40, and protease inhibitor tablet (Roche), 5.7 mM b-mercaptoethanol) and passed
through a 21G needle. 750U benzonase (Sigma) was added and samples were sonicated for 10 cycles of 30 sON/OFF at 30%ampli-
tude (Branson Digital Sonifier). NaCl concentration was increased to 300mMand samples were centrifuged at 31,000 g (30min, 4◦C)
and the supernatant was transferred to new tubes. His-tagged proteins were purified using 0.5 mL NiSO4-coated Chelating Sephar-
ose Fast Flow beads (GE healthcare), incubated in lysates for 1 hr at 4◦C. Beads were washed three times in 12 mL lysis buffer (with
300 mM NaCl) and protein was eluted in five fractions each of 0.5 mL lysis buffer with 250 mM imidazole. Fractions were pooled and
diluted with 5-10 mL HEPES buffer (20 mM HEPES, 300 mM NaCl, 1 mM EDTA). The samples subsequently purified using a HiTRap
Sp Hp 1 mL Column (GE Healthcare) to select for positively charged proteins. Columns were washed with 10 mL HEPES buffer and
protein was eluted in 1 mL HEPES buffer with 0.7 M NaCl (fraction 1) and then 1 mL 1 M NaCl (fraction 2). Fraction 2 was used in the
EMSA experiments.
Bio-Layer Interferometry (BLI)
Single-stranded DNA probes were purchased from Integrated DNA Technologies (IDT) and annealed by heating at 95C for 5min and
slowly cooled down at room temperature. See Key resources table for sequences.
The dissociation constant (KD) of MeCP2[MBD] to different DNA probes was determined by using bio-layer interferometry on the
Octet RED384 system (ForteBio, Pall). All assays were performed in low-binding black 96 well plates (Greiner) with 1,000 rpm orbital
shaking and samples were diluted in freshly prepared and filtered BLI buffer (150mM NaCl, 10mM HEPES, pH8.0 and 0.05%
Tween20).
First, streptavidin biosensors (18-5019, ForteBio, Pall) were hydrated in 200 ml of BLI buffer for 20 min at room temperature. Then,
50-biotinylated double-stranded DNA probes (6 nM, final concentration) were loaded on the streptavidin biosensors for 600sec fol-
lowed by quenching with biotin (5 mg/ml, final concentration) for 50 s. The DNA-loaded sensors were then submerged in wells con-
taining increasing concentrations of MeCP2[MBD] (0-375nM) in the presence of poly(dI-dC) (1mg/ml, final concentration) (LightShift,
Thermo) for 600 s followed by 300 s of dissociation time.
Electromobility shift assay (EMSA)
For the EMSAwithMBD2[MBD], single-stranded FAM-labeled DNA probes were purchased from Integrated DNA Technologies (IDT)
and annealed by heating at 95C for 5 min and slowly cooled down at room temperature. See Key resources table for sequences.
Assays were assembled in 10 ml reactions in binding buffer containing 20 mM HEPES (pH7.9), 150 mM KCl, 8% Ficoll, 1 mM
EDTA and 0.5 mM DTT. The protein (2 mM final concentration) was incubated in binding buffer for 10 min at room temperature,
then poly(dI-dC) (LightShift, Thermo) was added at a final concentration of 40 ng/uL and the reaction incubated for 10 min at
room temperature. 50-FAM-labeled DNA probe (10 nM final concentration) was added and incubated a further 25 min at room tem-
perature. The reactions were run on a 4.0%acrylamide (ratio 37:1, Sigma) Tris Borate EDTA gel in 0.25X TBE, 150V for 3 hours at 4C.
The bandshifts were exposed at 473 nm on a fluorescent scanner (FujiFilm FLA-5100) and gel images were visualized with the soft-
ware FujiFilm MultiGauge.
EMSAs with MeCP2[N-term] and MM2[N-term] were performed as described previously (Brown et al., 2016). Single-strand oligo-
nucleotide probes from the mouse Bdnf promoter region were purchased from Biomers, Germany, annealed by heating at 100C for
10 min and slowly cooled to room temperature. Probe sequences contained a central methylated, or unmethylated CG or CAC site
(see Key resources table for sequences). 500 ng of probewas radio-labeled using T4 polynucleotide kinase (NEB) and purified (MinE-
lute PCR Purification Kit, QIAGEN) according tomanufacturer’s instructions. 1 ng probe and 1 mg poly deoxyadenylic-thymidylic acid
competitor DNA (Sigma-Aldrich) were added with 0, 1.5, 3.0 or 4.5 uM polypeptide in reaction buffer (5% glycerol, 0.1 mM EDTA,
10mMTris HCl pH 7.5, 150mMKCl, 0.1mg/ml BSA) on ice for 20minutes. Samples were run at 120 V for 70min on a 10%acrylamide
Tris Borate EDTA gel (0.075% APS, 0.00125% TEMED) in chilled TBE. The gels were exposed overnight and imaged using the
Typhoon FLA 9500 scanner (GE Healthcare).
DNA pull-down assay
This assay performed as described previously (Connelly et al., 2020)(Piccolo et al., 2019). PCR-generated, biotin end-labeled 147 bp
DNA probes (2 mg) were coupled to M280-streptavidin Dynabeads according to the manufacturer’s instructions (Invitrogen). All cy-
tosines in the probes were either non-methylated or methylated and only occurred in a single sequence context (CG, CAC or CAT),
sequences in the Key resources table. Bead-DNA complexes were then co-incubated with 20 mg of rat brain nuclear protein extract
(Mellén et al., 2017) for 1.5 hours at 4◦C. Following extensive washing, bead-bound proteins were eluted using Laemmli buffere7 Molecular Cell 81, 1260–1275.e1–e12, March 18, 2021
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MeCP2 (Sigma M6818; RRID:AB_262075) diluted 1:1000; with secondary detection employing Li-COR IRDye 800CW Donkey
anti-Mouse (926-32212) diluted 1:10,000, then scanned using a LI-COR Odyssey CLx machine.
MeCP2 localization and TBL1X–mCherry recruitment assay
Analysis of MeCP2 localization and recruitment of TBL1X was performed as done previously (Lyst et al., 2013; Tillotson et al., 2017).
NIH 3T3 cells were seeded on coverslips in six-well plates (25,000 cells per well) and transfected with 2 mg plasmid DNA (pEGFP-N1–
MeCP2 alone or pEGFP- N1–MeCP2 and pmCherry-N1–TBL1X5) using JetPEI (PolyPlus Transfection). After 48 h, cells were fixed
with 4% (w/v in PBS) paraformaldehyde (Sigma), stained with 40, 6- diamidino-2-phenylindole (DAPI; Sigma) and thenmounted using
ProLong Diamond (Life Technologies). Images were acquired on a Leica SP5 laser scanning confocal and a HCX PLAPO 63x/1.4
objective with laser lines for DAPI (405nm), GFP (488nm) and mCherry (594nm) selected using LAS AF software (Leica).
Fluorescence recovery after photobleaching (FRAP)
NIH 3T3 cells were seeded on poly-L-lysine-coated coverslips in six-well plates (200,000 cells per well) and transfected with 2 mg
plasmid DNA using JetPEI (PolyPlus Transfection). After 40-48 h, coverslips were used for live cell imaging at 37C, 5%CO2. Images
were acquired on a Zeiss LSM880 laser scanning confocal equippedwith aGaSP detector and a Plan-Apochromat 63x/1.4 objective.
A z stackwas acquired at each time point comprising of six Z positions spaced 1 mmapart to account for any vertical movement of the
bleach position in the cell. Images were acquired using a 488 nm laser at 0.2% power to minimize any photobleaching, except for the
bleach spot (diameter 10 pixels = 1.6 mm) that was exposed to 100% laser power for 0.5 s (sufficient to produce an 80% decrease in
the intensity at the bleach spot). A total of 295 post bleach images (1.02 s apart) were taken to ensure any recovery wasmeasured to a
steady state. Five images were taken before the bleach, the mean of which was used as the ‘‘preBleach’’ values. At least two cells
were included in each frame, the first containing the bleach spot and the second as a control to correct for photobleaching during the
course of the experiment.
Immunohistochemistry
Mice were culled using CO2 at 14-15 weeks, and as soon as death could be confirmed, the rib cage was opened up to expose
the heart. Animals were perfused with 1 mL Lidocaine (1% in PBS) followed by 25 mL 4% paraformaldehyde (w/v) in PBS
(Sigma) pumped at 7 ml/min through the circulatory system. Brains were stored overnight in 4% PFA (w/v) in PBS before incu-
bation in 30% sucrose (w/v) in PBS overnight and flash frozen in isopentane. 10 mm sections were cut on a Leica CM1900 cryo-
stat at 18C. Sections were washed twice in PBS, permeablised in 0.1% (v/v) Triton-100 in PBS (15 min), washed again and
blocked in 1.5% goat serum. They were then probed with a Cy3-conjugated antibody against NeuN (Millipore MAB377C3;
RRID: AB_10918200) overnight at 4C. Sections were washed once in PBS, incubated in 1 mg/ml DAPI (10 min), washed twice
more and mounted with coverslips using Prolong Diamond (ThermoFisher Scientific). Images of sections were acquired on a
Zeiss LSM880 laser scanning confocal and a Plan Apochromat 63x/1.4 objective with laser lines for DAPI (405nm), GFP
(488nm) and Cy3 (561 nm) selected using Zen Black software (Zeiss). Images show neurons in the dentate gyrus of the
hippocampus.
Immunoprecipitation and western blotting
HeLa cells were transfected with pEGFP-N1–MeCP2 plasmids using JetPEI (PolyPlus Transfection) and harvested after 24–48 h.
Fresh or frozen cell pellets were Dounce homogenized in 1.5 mL in NE1 (20 mM HEPES pH 7.5; 10 mM NaCl; 1mM MgCl2; 0.1%
Triton X-100; 10 mM b-mercaptoethanol; protease inhibitor tablet (Roche)). Snap-frozen brain hemispheres (harvested at 8-
18 weeks of age) were Dounce homogenized in 2.5 mL NE1. Nuclei were collected by centrifugation at 845 g (5 min, 4◦C) and
resuspended in NE1 (HeLa nuclei 200 ml; brain nuclei 2 ml). Nuclei were treated with 250 U/500 U Benzonase (Sigma) for 5 min
at room temperature before increasing NaCl concentration to 150 mM and incubated under rotation for 20 min at 4◦C. Samples
were centrifuged at 16,000 g (20 min, 4◦C) and the supernatant was taken as the nuclear extract. MeCP2–EGFP complexes were
captured from nuclear extract using GFP-Trap_A beads (Chromotek) under rotation at 4C for 20-30 min. Beads were washed four
times in NE1 containing 150mMNaCl and then proteins were eluted in 2x Laemmli Sample Buffer (Sigma) at 100C, 5min. Proteins
were analyzed by western blotting using antibodies against MeCP2 (SigmaM7443; RRID:AB_477235) at a dilution of 1:2,000, GFP
(NEB 2956; RRID: AB_1196615), NCOR1 (Bethyl A301-146A; RRID: AB_873086), TBL1XR1 (Santa Cruz sc-100908; RRI-
D:AB_1130006) or HDAC3 (Sigma 3E11; RRID: AB_1841895), all at a dilution of 1:1,000. For detection on a LI-COR Odyssey
CLx machine, blots were probed with LI-COR secondary antibodies: IRDye 800CW Donkey anti-Mouse (926-32212), IRDye
800CW Donkey anti-Rabbit (926-32213) or IRDye 680LT Donkey anti-Rabbit (926-68023) at a dilution of 1:10,000. For detection
by ECL, blots were probed with anti-mouse-HRP (GE Healthcare, NA931) or anti-rabbit-HRP (GE Healthcare, NA934) at a dilution
of 1:5,000.
Protein levels in whole-brain crude extracts were quantified usingwestern blotting. Frozen half-brains (harvested at 9weeks of age)
were Dounce homogenized in 750 mL cold NE1 (20 mM HEPES pH7.9, 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100, 20% glycerol,
0.5 mM DTT, and protease inhibitors (Roche)) and treated with 750 U Benzonase (Sigma) for 15 min at room temperature. Next,
750 mL of 2x Laemmli Sample Buffer (Sigma) was added and samples were boiled for 3 min at 100C, snap-frozen on dry ice, andMolecular Cell 81, 1260–1275.e1–e12, March 18, 2021 e8
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with an antibody against MeCP2 (SigmaM7443; RRID:AB_477235) at a dilution of 1:1,000, followed by LI-COR secondary antibodies
(listed above). Histone H3 (Abcam ab1791) was used as a loading control (dilution 1:10,000).
Flow cytometry
Fresh brains were harvested from 12-week-old animals and Dounce-homogenized in 5 mL homogenization buffer (320 mM sucrose,
5 mM CaCl2, 3 mMMg(Ac)2, 10 mM Tris HCl pH 7.8, 0.1 mM EDTA, 0.1% NP40, 0.1 mM PMSF, 14.3 mM b -mercaptoethanol, pro-
tease inhibitors (Roche)), and 5 mL 50% OptiPrep gradient centrifugation medium (50% Optiprep (Sigma D1556-250ML), 5 mM
CaCl2, 3 mM Mg(Ac)2, 10 mM Tris HCl pH 7.8, 0.1 M PMSF, 14.3 mM b -mercaptoethanol) was added. This was layered on top
of 10 mL 29%OptiPrep solution (v/v in H2O, diluted from 60% stock) in Ultra-Clear Beckman Coulter centrifuge tubes, and samples
were centrifuged at 10,100 g (30 min, 4C). Pelleted nuclei were resuspended in resuspension buffer (20% glycerol in DPBS (GIBCO)
with protease inhibitors (Roche)). For flow cytometry analysis, nuclei were pelleted at 600 g (5 min, 4C), washed in 1 mL PBTB (5%
(w/v) BSA, 0.1% Triton X-100 in DPBS with protease inhibitors (Roche)) and then resuspended in 250 ml PBTB. To stain for NeuN,
NeuN antibody (Millipore MAB377) was conjugated to Alexa Fluor 647 (APEX Antibody Labeling Kit, Invitrogen A10475), added at
a dilution of 1:125 and incubated under rotation for 45 min at 4C. Flow cytometry (BD LSRFortessa SORP using FACSDIVA version
8.0.1 software) was used to obtain the mean EGFP fluorescence for the total nuclei (n = 50,000 per sample) and the high-NeuN
(neuronal) subpopulation (n > 8,000 per sample). Three biological replicates of each genotype were analyzed.
ATAC-seq library preparation
Hypothalami were dissected fromMM2-EGFP (n = 3),Mecp2 null (KO) (n = 3) andWT (n = 4, 3MM2-EGFP littermates and 1 KO litter-
mate) mice at 6-7 weeks of age. Freshly dissected tissues were homogenized using a hypotonic buffer (10 mM Tris-HCl pH 7.4,
10 mM NaCl, 3mM MgCl2, 0.1% [v/v] Igepal CA-630). Isolated nuclei were counted, and 50,000 nuclei were resuspended in 50 ml
of a transposition reaction mix containing 2.5 ml Nextera Tn5 Transposase and 2x TD Nextera reaction buffer. The mix was incubated
for 30min at 37 ◦C. DNAwas purified by either theMinElute PCR kit (QIAGEN) or the Agencourt AMPure XP beads (BeckmanCoulter)
and PCR amplified with the NEBNext High Fidelity reaction mix (NEB) to generate DNA libraries. The libraries were sequenced as
75 bp paired-end reads on a HiSeq 2500 Illumina platform.
RNA-seq library preparation
Hypothalami were harvested at 6-7 weeks of age (referred to as ‘‘6 weeks’’) fromMecp2 null (KO) mice (n = 4) and their WT littermate
controls (n = 3) and MM2-EGFP mice (n = 3) and their WT littermate controls (n = 4); and at 12-15 weeks of age (referred to as
‘‘12 weeks’’) fromMM2-EGFPmice (n = 4) and their WT littermate controls (n = 4). Total RNA was isolated from mouse hypothalami
using Qiazol lysis reagent followed by purification with the RNeasyMini kit (QIAGEN) according to manufacturer’s protocol. Genomic
DNA contamination was removed with the DNA-free kit (Ambion) and remaining DNA-free RNA was tested for purity using PCR for
genomic loci. Total RNA was tested on the 2100 Bioanalyzer (Agilent Technologies) to ensure a RIN quality higher than 9, and quan-
tified using a Nanodrop. Equal amounts of total RNA were taken forward for library preparation and ERCC RNA Spike-in control mix
(Ambion) was added according to the manufacturer’s guide. Ribosomal RNA was depleted using the RiboErase module (Roche) fol-
lowed by library preparation using KAPA RNA HyperPrep Kit (Roche). The libraries were sequenced as 50 bp pair-end reads using a
Nova-seq Illumina platform.
Phenotypic analysis
Consistent with previous studies (Brown et al., 2016; Tillotson et al., 2017), mice were backcrossed for four generations onto C57BL/
6J before undergoing phenotypic characterization. Two separate cohorts, each consisting of 10 MM2-EGFP animals and 10 wild-
type littermates, were produced. One cohort was scored weekly from 4 weeks of age (excluding week 31) until each mutant reached
its humane end-point (wild-type controls until 52 weeks) using a system developed by Guy et al. (2007). Two wild-type controls were
culled due to injuries, aged 38 and 45 weeks (censored on survival plot). Mice were scored in six categories: spontaneous activity,
gait, hind-limb clasping, tremor, abnormal breathing and general appearance. Mice received a score between 0 and 2 for each cate-
gory, where 0 = as wild-type, 1 = present, and 2 = severe. Intermediate scores of 0.5 and 1.5 were also used in all categories except
hind-limb clasping (Cheval et al., 2012). The scores in each category were added together to give the aggregate symptomatic score
for each animal. The mean scores ± SEM for all animals were plotted over time. Animals were also weighed during scoring sessions.
Animals were culled if they lost more than 20% of their maximum body weight. Survival was graphed using Kaplan–Meier plots. Pre-
viously published (Brown et al., 2016) data for Mecp2 null, T158M-EGFP, R306C-EGFP and R133C-EGFP (all backcrossed onto
C57BL/6J) were used for comparison. Scoring: null (n = 12), T158M-EGFP (n = 7), R306C-EGFP (n = 11) R133C-EGFP (n = 10); sur-
vival: null (n = 24), T158M-EGFP (n = 11), R306C-EGFP (n = 11), R133C-EGFP (n = 10); body weight: null (n = 20), T158M-EGFP (n =
15), R306C-EGFP (n = 11), R133C-EGFP (n = 10). Scoring data for the MM2-EGFP, R306C-EGFP and R133C-EGFP cohorts was
plotted as heatmaps shaded according to the mean score for each category per week (aligned by age and time before death).
Two R133C animals survived to one year of age so were excluded from the scoring analysis for the five weeks before death.
Some animals reached their humane point > 4 days after they were last scored so were included in weeks5 to1 only; for 0 weeks
prior to death: MM2-EGFP (n = 7), R306C-EGFP (n = 8), R133C-EGFP (n = 8).e9 Molecular Cell 81, 1260–1275.e1–e12, March 18, 2021
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et al., 2016). Tests were performed over a twoweek period: elevated plusmaze on day 1, open field test on day 2, hangingwire on day
3 and accelerating rotarod on days 6–9 (1 day of training followed by 3 days of trials). The elevated plus maze is a cross-shapedmaze
65 cm above the floor with two open arms (20 3 8 cm), two closed arms (20 3 8 cm, with 25 cm high walls) and a central area (8 3
8 cm). It is set up in a dimly lit room with uniform lighting between each of the closed arms and each of the open arms. Animals were
placed in the central area and left to explore for 15 min (during which the experimenter left the room). Mice were tracked using ANY-
maze software (Stoelting) and the time in each area was determined. Mice were deemed to be in a particular area of the maze if R
70% of their body was inside this region. The open field apparatus used consisted of a square arena measuring 50 by 50 cm, which
was evenly lit (in a dimly lit room) and littered with fresh wood chippings. The animals were placed in the center of the area and left to
explore for 20 min each (during which the experimenter left the room). Mice were tracked using ANYmaze software (Stoelting). Ac-
tivity was assessed by total distance traveled. The hanging wire apparatus consists of a 1.5 mm diameter horizontal wire, 35 cm
above the bench. Animals were placed on the wire with their forepaws by the experimenter, and the time taken to bring a hind
paw to the wire was recorded. Animals were given a maximum of 30 s to complete this task. Animals that took longer or fell off
the wire were given the maximum score of 30 s. The test was performed three times for each animal (with an inter-test interval of
30 min) and the mean of the three tests was calculated. The accelerating rotarod consisted of a 3 cm diameter rod that can rotate
between 4 and 40 revolutions per minute (rpm). On the first day, the animals were accustomed to the apparatus in a short training
session where they must stay on the track for 30 s at its lowest speed (4 rpm). On the subsequent three days, each animal underwent
four trials (with an inter-trial interval of 75min) where the speed is slowly increased from 4 rpm to 40 rpm over 5min. The time taken to
fall (latency) was recorded and the average time for each day was calculated.
All analysis was performed blind to genotype. Animals were randomly assigned to the two backcrossed cohorts and the order in
which they were analyzed was randomized. Cohorts of this size have been used to successfully detect RTT-like symptoms in mice
carrying patient mutations including the milder mutation, R133C (Brown et al., 2016).
QUANTIFICATION AND STATISTICAL ANALYSIS
Information on sample size, definition of center and dispersion, the statistical tests used and the resulting P values are included in the
figure legends. All statistical analysis was performed using Prism 8 Software. Significance was defined as p < 0.05.
Evolutionary conservation among MBD proteins
The primary protein sequences of the methyl-CpG binding domains (MBDs) of human and mouse MeCP2, MBD1, MBD2 and MBD4
were aligned using ClustalWS on Jalview 2.8.2.
BLI quantification
The binding sensorgrams were analyzed using the Octet data analysis software 9.0 (ForteBio, Pall). Experimental data were fitted
using a 2:1model with global fitting (Rmax unlinked by sensors). All experiments were repeated on three independent protein batches
and data represents the mean of high-confidence KD (fit R
2 > 0.9 and narrow CI). KD values were compared using t tests (unpaired,
two-tailed).
EMSA quantification
Percentage shift of the probe in electromobility shift assays (EMSAs) were quantified using ImageJ (NIH) from three technical repli-
cates. Binding affinities were compared using Two-way ANOVA.
Quantification of TBL1X recruitment
The number of co-transfected cells with TBL1X–mCherry recruitment to heterochromatic foci was determined for each MeCP2
construct. Three independent transfections were performed, and a total of 156, 150 and 151 cells were counted that expressed
WT-EGFP, R306C –EGFP and MM2-EGFP, respectively. This analysis was performed blind. The total proportion of cells with
TBL1X–mCherry recruitment by each mutant MeCP2 protein was compared with WT using Fisher’s exact tests.
FRAP analysis
FRAP analysis was performed on NIH 3T3 cells transiently transfected with EGFP-tagged WT (n = 27) and MM2 (n = 28), over inde-
pendent three transfections. Imageswere analyzed using a custom plugin (GitHub: https://doi.org/10.5281/Zenodo.2654602) written
for ImageJ (NIH). Fluorescence values were normalized using the following equation:
Normalised fluorescence =
Mean Cell Control preBleach BackgroundðtÞ
Control Cell BleachðtÞ  BackgroundðtÞ 
ðFrapSpotðtÞ  BackgroundðtÞ
Mean FrapSpot preBleach BackgroundðtÞ
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ments) and F0 = the fluorescence minimum at t0 (first image after the bleach); logarithmic regression lines were used (calculated in
Microsoft Excel, between 0 and 150 s as the curves fitted a logarithmic trend in this portion). The half-lives reported are the mean ±
SEM calculated from the replicate cells. The half-lives of WT-EGFP and MM2-EGFP where compared using a Mann-Whitney test.
Quantification of western blots
Western blots were processed using Image Studio Lite version 5.2 software. Protein levels of WT-EGFP and MM2-EGFP were
compared using a t test (unpaired, two-tailed).
Quantification of flow cytometry
Protein levels in neuronal nuclei were quantified by EGFP fluorescence by Flow cytometry (BD LSRFortessa SORP using FACSDIVA
version 8.0.1 software) to obtain the mean EGFP fluorescence for the total nuclei (n = 50,000 per sample) and the high-NeuN
(neuronal) subpopulation (n > 8,000 per sample). Three biological replicates of each genotype were analyzed. The protein levels in
MM2-EGFP mice were compared with WT-EGFP controls using t tests (unpaired, two-tailed).
Quantification of microscopy
Images of the dentate gyrus of the hippocampus were processed and quantified using Fiji (ImageJ). Pericentromeric chromatin was
defined as DAPI foci above a fixed brightness threshold. The sum of the area of these foci was divided by the cell number to calculate
the area of pericentromeric heterochromatin per cell. Total number of cells per genotype: WT-EGFP n = 967; MM2-EGFP n = 1129,
from three biological replicates of each (WT-EGFP1 n = 386; WT-EGFP2 n = 318; WT-EGFP3 n = 263; MM2-EGFP1 n = 533; MM2-
EGFP2 n = 359; MM2-EGFP3 n = 237). Graphs show mean ± SEM of the three biological replicates and genotypes were compared
using t tests (unpaired, two-tailed).
Quantification of genomic cytosine methylation
To calculate the percentage methylation in the Whole genome bisulphite sequencing data (GEO: GSE84533) (Lagger et al., 2017), a
threshold of R 5-fold coverage was used. The proportion of methylation for each site was determined based on the reads covering
the site for eachmotif, and the sum of these values was divided by the number of times that motif occurred. To determine the number
of sites with different levels of methylation (100%, 75%–99%, 50%–74%, 25%–49%, 1%–24% and 0%), a threshold of R 5-fold
coverage was used. To calculate the approximate number of sites with different levels of methylation in the whole genome, these
values were multiplied by total number of motifs in the genome/number of motifs with R 5-fold coverage.
Analysis of ATAC-seq footprinting
Nextera adaptor sequence removal was performed on 75 bp paired-end reads using Trimmomatic version 0.32 with the following
parameters: ILLUMINACLIP:nextera.fa:2:40:15 MINLEN:25. Surviving reads were then mapped to the mouse mm9 reference
genome with bwa mem version 0.7.5a-r405 using the -M parameter. Alignments were filtered based on mapping quality (< 20) so
that only uniquely mapped reads were taken forward, furthermore, reads aligning to mitochondrial DNA or Encodemm10 blacklisted
regions were removed from further analysis. Read alignments were converted into normalized coverage files for visualization and
downstream quantification using deepTools bamCoverage version 3.1.3 with the following parameters: -bs 1–normalizeUsing
BPM–skipNAs -e. The positions of Tn5 transposase cutsites were inferred from the 50 end of aligned sequencing reads and converted
into bigWig format for further analysis.
Whole genome bisulphite sequencing data (GEO: GSE84533) (Lagger et al., 2017) was employed to visualize a footprint of MeCP2
binding across methylated and unmethylated cytosines in several sequence contexts. For mCG, 1 million randomly selected sites
with 100%methylation (R5-fold coverage between both strands) were used. For CG, sites with 0%methylation (R10-fold coverage
between both strands) were used (n = 935,582). FormCAC, sites withR 75%methylation (R5-fold coverage) were used (n = 95,017).
To increase the number of sites used, the thresholds were lowered toR 4-fold coverage andR 50%methylation for other forms for
mCH: mCAT n = 167,159; mCAG n = 172,250; mCAA n = 72,688; mCT n = 263,578; mCC n = 7,643. For all unmethylated CHmotifs, 1
million randomly selected sites with 0% methylation (R10-fold coverage) were used. The distribution of ATAC-seq cut sites around
methylated and unmethylated cytosines was computed in R using the seqPlots package. The region 300 bases upstream and down-
stream of each cytosine was divided into single base bins and for each bin the total number of cut sites was summed across all cy-
tosines. These values were plotted to show the number of cut-sites in the 600 bases surrounding cytosines of different methylation
context. The values were normalized to the flanking regions by calculating the ratio of each bin to the mean of all bins within the outer
100 bases of the plot. For each sample themean values of each bin were computed across all biological replicates before plotting. To
determine footprints of MeCP2-dependent or MM2-EGFP-dependent chromatin inaccessibility, ATAC-seq profiles over each motif
were divided by the equivalent KO profile. Graphs show ln(WT/KO) or ln(MM2-EGFP/KO). To directly compare occupancy of mCG
sites between WT and MM2-EGFP proteins, graphs show ln(MM2-EGFP/WT).e11 Molecular Cell 81, 1260–1275.e1–e12, March 18, 2021
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Raw sequencing reads were quality and adaptor trimmed using Trimmomatic v0.33 (Bolger et al., 2014). Quality trimmed reads were
aligned to mm10 genome assembly andM19 transcriptome assembly using STAR v2.4.2a (Dobin et al., 2013) and read counts span-
ning exons were calculated using featureCounts v1.6.4 (Liao et al., 2014). Differential gene expression analysis was performed using
DESeq2 v1.24.0 (Love et al., 2014) and significance threshold for a gene was set at p-adjusted value < 0.05.
Whole genome bisulphite sequencing data (GEO: GSE84533) (Lagger et al., 2017) was used to determine the number of mCG and
mCAC binding sites per gene body (between the transcriptional start site and transcriptional termination site). The proportion of DNA
methylation at a given site i corresponds to the ratio of methylated C basecalls (mC) for that site to the count of all reads mapping to
that site (mi = mC / C). The total number of methylated sites for CG and CAC motifs across a gene body was calculated by summing
the respectivemi. Since a single molecule of an MBD protein binds a symmetrically methylated mCG/mCG site, the number of mCG
sites was divided by two. Ordinary least-squares (OLS) linear regression analysis was used to compare the number of mCG versus
mCAC binding sites per gene. Comparisons of gene expression changes to the number of methylated binding sites used all genes
that were detected in all datasets (n = 14,391). Gene expression changes were determined by comparing the following pairs of data-
sets: KO/WT (littermate controls, at 6 weeks on C57BL/6J;CBA/CA),MM2-EGFP/WT (littermate controls, at 6 weeks on C57BL/6J),
MM2-EGFP/WT (littermate controls, at 12 weeks on C57BL/6J). Genes were binned by the number of mCG or mCAC binding sites,
each bin contained 500 genes (the first and last bins were excluded due to the high variance in the motif used for binning. Slopes of
linear regression (with 95% confidence interval) were determined and plotted for each bin. For each bin, it was determined whether
the slope was significantly non-zero. The ratio of mCG/total binding sites was calculated for genes in each of the mCAC bins and the
ratio of mCAC/total binding sites was calculated for genes in each of the mCG bins. Total = mCG + mCAC. Table S5 (Excel file) con-
tains expression change and methylation data for the 14,391 expressed genes.
Genes significantly dysregulated in mutants compared to age-matched wild-type littermate controls were identified in each data-
set (KO/WT, 6 weeks;MM2-EGFP/WT 6weeks; andMM2-EGFP/WT, 12 weeks) using an adjusted p value (padj) of < 0.05. OLS linear
regression analysis was used to compare transcriptional changes of shared genes in WT/KO (6 weeks) versus MM2-EGFP/WT
(6 weeks) and in WT/KO (6 weeks) versus MM2-EGFP/WT (12 weeks). Comparisons between the shared differentially expressed
genes and those dysregulated in KO or MM2-EGFP only were performed separately on the age-matched and symptom-matched
datasets. This analysis compared: the total number of mCG + mCAC binding sites per gene, the ratio of mCAC/total binding sites
per gene and expression changes (relative to wild-type littermate controls). Shared genes were statistically compared to those un-
changed in either mutant and to those affected in KO or MM2-EGFP only using Mann-Whitney tests. Expression changes of the
neurological disease-associated genes from previously published RNA-seq datasets were added for comparison: KO/WT hypothal-
amus 6 weeks (GEO: GSE66870) (Chen et al., 2015) and KO/WT cortex 8 weeks (GEO: GSE128178) (Boxer et al., 2019).
Disease Ontology analysis
Dysregulated gene identifiers were converted to theirH. sapiens orthologs and disease ontology enrichment analysis was performed
using clusterProfiler (Yu et al., 2012). Over representation analysis (ORA) was used to determine whether any known disease ontol-
ogies are over-represented in the list of dysregulated genes. Hypergeometric test was used to estimate the significance of the dis-
ease ontologies and p values were adjusted to account for Type I errors using Bonferroni correction. Type I errors were also ac-
counted for using a separate independent method called Benjamini/Hochberg correction to calculate false-discovery rates (FDR).
Statistical analysis of behavioral data
Growth curves were compared usingMixed-effects model (REML) analysis for weeks 4-48 (excluding week 31). Survival curves were
compared using a Mantel–Cox test. For behavioral analysis, when all data fitted a normal distribution (open field), genotypes were
compared using t tests (unpaired, two-tailed). For non-parametric datasets (elevated plus maze, hanging wire and accelerating ro-
tarod latency to fall), genotypes were compared using Kolmogorov–Smirnov tests. Change in performance over time in the acceler-
ating rotarod test was determined for each genotype using Friedman tests.Molecular Cell 81, 1260–1275.e1–e12, March 18, 2021 e12
